Novartis drops pursuit of Gen-Probe - WSJ
CHICAGO, July 19
CHICAGO, July 19 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) is no longer actively pursuing a purchase of diagnostic test maker Gen-Probe Inc GPRO.O, the Wall Street Journal said, citing people familiar with the matter.
Shares of Gen-Probe, a maker of tests for infectious diseases, fell $2.51, or 3.92 percent, to $61.48 after the report.
Novartis was thought to be the sole remaining suitor for Gen-Probe after other potential buyers including Life Technologies CorpLIFE.O and Thermo Fisher Scientific Inc (TMO.N) ended their pursuit last month, the sources told the Journal in a story on its website.
Another bidder could still emerge because the sale process is ongoing, other people familiar with the matter told the Journal.
A Novartis spokeswoman declined to comment on the report.
A spokesman for San Diego-based Gen-Probe, a maker of tests for infectious diseases, also declined to comment.
(Reporting by Susan Kelly, editing by Bernard Orr)
- Nearly 300 missing after South Korean ferry capsizes: coastguard |
- Separatists fly Russian flag over Ukrainian armored vehicles
- Ocean floor search for missing Malaysia plane cut short again
- Ukraine launches 'gradual' operation, action limited |
- China economic growth slows to 18-month low in first-quarter |